Can new antibodies make dialysis safer by preventing clots without bleeding?

NCT ID NCT07759167

Not yet recruiting Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests three experimental antibodies—REGN9933, REGN7508, and REGN9533—in people with end-stage kidney disease who are on hemodialysis. The goal is to see if these antibodies can safely reduce blood clot risk during dialysis, potentially offering an alternative to standard heparin. The study focuses on safety, how the antibodies behave in the body, and their effect on blood clotting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Three experimental monoclonal antibodies (REGN9933, REGN7508, REGN9533) that target clotting proteins, given alongside standard heparin anticoagulation.
What this could lead to: If successful, these antibodies could offer a safer way to prevent blood clots during dialysis, reducing bleeding complications for people with end-stage kidney disease.
What could go wrong: This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. The antibodies may not work as hoped or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE KIDNEY DISEASE (ESKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure Hemorrhage thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE KIDNEY DISEASE (ESKD)

More trials for these conditions

Other studies related to the condition(s) this trial covers.